| Identification | Back Directory | [Name]
APX-115 freebase | [CAS]
1270084-92-8 | [Synonyms]
APX-115 freebase
Ewha-18278 free base
1H-Pyrazol-5-ol, 3-phenyl-4-propyl-1-(2-pyridinyl)- | [Molecular Formula]
C17H17N3O | [MOL File]
1270084-92-8.mol | [Molecular Weight]
279.34 |
| Chemical Properties | Back Directory | [Boiling point ]
493.3±45.0 °C(Predicted) | [density ]
1.17±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO: Sparingly Soluble: 1-10 mg/ml
Ethanol: Sparingly Soluble: 1-10 mg/ml | [form ]
Solid | [pka]
7?+-.0.50(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
APX-115 free base (Ewha-18278 free base) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base effectively prevents kidney injury[1]. | [in vivo]
APX-115 free base (oral gavage; 60?mg/kg/day; for 12 weeks) significantly improves insulin resistance in diabetic mice[2].
APX-115 free base treatment decreases the urinary excretion of albumin and plasma creatinine levels[2].
| Animal Model: | Six-week-old male diabetic db/db mice (C57BLKS/J-leprdb/leprdb)[2] | | Dosage: | 60?mg/kg | | Administration: | Oral gavage; per day; for 12 weeks | | Result: | Significantly improved insulin resistance in diabetic mice.
|
| [IC 50]
NOX1; NOX2; NOX4 | [References]
[1] Kwon G, et al. A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis. Oncotarget. 2017 Jun 16;8(43):74217-74232. DOI:10.18632/oncotarget.18540
[2] Cha JJ, et al. APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury. Lab Invest. 2017 Apr;97(4):419-431. DOI:10.1038/labinvest.2017.2 |
|
| Company Name: |
Twochem Co.Ltd.
|
| Telephone: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|